BMI decreases predict poor prognoses for patients with advanced CRC, and normal BMI was a predictive factor for high survival rate. Thus, BMI appears to be an independent predictive factor of CRC survival rates. Objectives To assess the prognostic value of BMI and outcome in both groups of patients: normal & abnormal (overweight and obese). Methods This study was done in medical oncology departments in Zagazig University and Maadi Military Hospital including all metastatic colorectal cancer patients in the duration January 2016 till January 2018 with total number of 186 patients. All patient were evaluated regarding epidemiological data and response to treatment and survival analysis. Results Median progression-free survival (PFS) of the whole studied sample (N=186 patients) was 9 months with higher PFS in patients receiving Anti-EGFR and patients with normal BMI. Obesity is also associated with poorer prognosis and outcomes with normal median overall survival in normal and abnormal (over weight and obese) (26 vs. 21 months) but it did not reach the significant value, and also regarding PFS was (10 vs. 9 months) respectively with no significant difference but denoting better numerical prognosis with normal BMI patients. There were others factors studied their relation to OS revealing significant correlation as receiving previous adjuvant treatment significantly increase overall survival (P=0.001), resection of primary tumor (P=0.001), site of metastasis with lymph nodes metastasis showing best overall survival up to 39 months (P=0.02), time of metastasis as metachronous metastasis showed higher overall survival